Newsadmin2019-05-15T18:58:21-04:00

News

Source: NASDAQ

EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect
Published on 2019-10-02
EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting
Published on 2019-09-27
EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Published on 2019-09-26
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting
Published on 2019-09-09
EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Published on 2019-08-07
EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
Published on 2019-07-30
EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS)
Published on 2019-07-25
EyePoint Pharmaceuticals Announces Second Quarter 2019 Financial Results Release Date and Conference Call Information
Published on 2019-07-24
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
Published on 2019-07-23
EyePoint Pharmaceuticals Appoints Wendy DiCicco, CPA, to Board of Directors
Published on 2019-07-15
EyePoint Pharmaceuticals Added to Russell 3000® and 2000® Indexes
Published on 2019-07-01
EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published on 2019-06-13
EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires
Published on 2019-06-10
EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
Published on 2019-05-15
EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
Published on 2019-05-08
EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Published on 2019-05-01
EyePoint Pharmaceuticals Announces First Quarter 2019 Financial Results Release Date and Conference Call Information
Published on 2019-04-23
EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences
Published on 2019-04-16
EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
Published on 2019-04-02
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Published on 2019-03-28